Amylin Pharmaceuticals

  • Can Regeneron Continue to Grow?     Monday, 2 Jul 2012 | 2:14 PM ET

    Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.

  • Bristol Buying Amylin for $7.1 Billion     Monday, 2 Jul 2012 | 2:11 PM ET

    CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.

  • $7.1 Billion Pharma Deal     Monday, 2 Jul 2012 | 1:11 PM ET

    CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.

  • Faber Report: Dish Network Drops AMC     Monday, 2 Jul 2012 | 9:38 AM ET

    CNBC's David Faber reports the Dish Network and AMC contract expired without a new agreement, and a look at the deal between Bristol-Myers and Amylin Pharma.

  • What's Next for Carl Icahn?     Monday, 30 Apr 2012 | 4:14 PM ET

    CNBC's David Faber speaks to activist investor Carl Icahn regarding how much cash he has available to invest and whether Chesapeake Energy is undervalued.

  • Carl Icahn, Icahn Enterprises chairman, discusses his tender offer for CVR Energy, and now holds 69% of the company's shares. Icahn also weighs in on whether Amylin Pharma should be sold, and reveals his thoughts on RIMM, with the Fast Money traders.

  • Amylin CEO Talks Pricing Strategy     Monday, 30 Jan 2012 | 4:45 PM ET

    Daniel Bradbury, Amylin CEO, explains the company's pricing strategy in Europe and how it will catch up with rival Novo Nordisk.

  • Amylin CEO on Exenatide     Tuesday, 8 Nov 2011 | 5:53 PM ET

    Dan Bradbury, Amylin CEO, discusses paying Lilly $250M upfront and $1.2B of future sales for the rights to Exenatide, the once weekly version of diabetes drug, Byetta, that's pending FDA approval.

  • Battling Diabetes Epidemic     Monday, 27 Jun 2011 | 3:27 PM ET

    Daniel Bradbury, Amylin president & CEO, discusses the company's new diabetes drug in Europe. Will it get approval in the US?